Physicians foresee an alzheimer's disease treatment revolution supported by advanced testing tools, new quest diagnostics report finds

Blood test for early detection of alzheimer's disease (ad) risk will lead to better patient care, physicians say; u.s. adults call for earlier evaluation and more education quest introduces widely available blood test to aid early assessment of ad risk; physicians believe ad blood tests will become standard of care secaucus, n.j. , may 2, 2022 /prnewswire/ -- quest diagnostics (nyse: dgx), the world's leading provider of diagnostic information services, today released a new research report,  the coming alzheimer's disease healthcare revolution: u.s. physician and adult perspectives on the future of diagnostics and treatment , that provides insights into the expectations and hopes of primary care physicians and american adults for the current and future landscape of dementia and ad testing, treatment and care.
DGX Ratings Summary
DGX Quant Ranking